CA-SYNTERACTHCR
10.11.2016 13:02:35 CET | Business Wire | Press release
Executives from SynteractHCR , a full-service, international contract research organization (CRO), are continuing to exhibit and speak at various industry conferences around the globe in November. The events include World Immunotherapy Congress, World Orphan Drug Congress Europe and Partnerships in Clinical Trials Europe. Each event brings together thought leaders from biotech, pharma and related industries to network and stay abreast of new developments and best practices.
The World Immunotherapy Congress , Nov. 14-16 at Congress Center in Basel, Switzerland, offers experts multiple opportunities to discuss the promising developments in immunotherapy, including immune checkpoint inhibitors and cell therapy. SynteractHCR will exhibit in booth #28 and will have clinical trial experts available to meet with companies that are focused on developing oncology and other therapeutic indication trials using immunotherapy techniques. To make an appointment to meet with SynteractHCR, contact Volker Knorz: Volker.Knorz@SynteractHCR.com .
The World Orphan Drug Congress Europe 2016 will be held Nov. 15-17 in Brussels, where Dr. Stephan de la Motte, chief medical advisor for SynteractHCR, will host two roundtables: the first on “Sharing Practical Insights on the Planning and Execution of Orphan Drug Clinical Trials ” at 11:30 am on Wed., Nov. 16th and the second on the same topic (time, date). Clients and others who might like to meet with the team at World Orphan may contact Alexandre Wallard: Alexandre.Wallard@SynteractHCR.com .
At the Partnerships in Clinical Trials Europe (PCT) event, Vice President for Global Medical and Regulatory Affairs Dr. Martine Dehlinger-Kremer will present : “Planning for the Impact of the New EU Clinical Trials Regulation and the Implications of the UK Brexit” from 11:25 a.m. – 12:00 p.m. EDT on Thursday, November 17th . Attendees will leave the presentation prepared for the upcoming EU Regulation and will better understand how Brexit may affect the new regulation. SynteractHCR will exhibit in booth #173.
Lastly, clinical trial experts from the company will also attend BVMA in Munich from Nov. 24-25th , 2016. Those who wish to meet with the team at either PCT or BVMA, or with Dr. Dehlinger-Kremer, may contact Xavier Morillon: Xavier.Morillon@SynteractHCR.com .
See SynteractHCR's full schedule of events and follow its social channels on LinkedIn and Twitter for live updates during all conferences.
About SynteractHCR
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision ” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005548/en/
Contact:
SynteractHCR
Beth Walsh, 760-230-2424
Beth@clearpointagency.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tangent Robotics Raises 4.5M in Pre-seed Funding to Advance Fine Motor Skills for Robot Dexterity30.9.2026 16:23:00 CEST | Press release
Fly Ventures and Toyota Ventures Lead Round on Columbia University Spinoff Fusing Robot Hands, Touch Sensing and Motor Learning In humans, fine motor skills can take two decades to fully develop. Tangent Robotics, which today announced its pre-seed funding round, aims to speed up the timeline for robots. The company will use the funds to develop skilled robotic manipulation capabilities at the intersection of hand hardware, touch sensing, and motor learning, and deploy them in demanding manufacturing environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930237631/en/ Tangent Robotics is developing fine motor skills for robot hands, which unlock the ability to perform critical tasks for what we want our economy to build locally, fast and at scale "Fine motor skills are hard to learn, and represent a layer that is currently missing in robotics but omnipresent in the real world," says Pedro Piacenza, Tangent's co-foun
Andersen Global styrker sin tilstedeværelse i Argentina med Fidem Partners30.9.2026 15:20:00 CEST | Pressemeddelelse
Andersen Global udvider sine kompetencer inden for skat og transaktioner i Argentina gennem en samarbejdsaftale med Fidem Partners og styrker dermed sin tilstedeværelse og sit serviceudbud på markedet. Fidem Partners blev stiftet i 2011 og rådgiver virksomheder om skat og compliance, fusioner og opkøb samt outsourcing af forretningsprocesser. Firmaet betjener virksomheder inden for energi, teknologi, finansielle tjenester, landbrug og forbrugsvarer og har stor erfaring med at rådgive datterselskaber af multinationale virksomheder i Argentina. Det bredt sammensatte team trækker på erfaring fra førende rådgivningshuse og erhvervslivet for at hjælpe virksomheder gennem de vigtigste udviklingsfaser. "Det meste af vores arbejde udfører vi for datterselskaber af multinationale virksomheder, der opererer i Argentina, hvor de regulatoriske rammer kræver dømmekraft – ikke kun compliance," udtalte Darío H. Díaz, managing partner hos Fidem Partners. "Samarbejdet med Andersen Global giver vores kl
Blue Matter Launches Behavioral Science Center of Excellence to Decode and Predict Health Care Decisions in a Rapidly Evolving Biopharma Landscape30.9.2026 15:00:00 CEST | Press release
Blue Matter today announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the Blue Matter Insights primary market research team. The CoE applies behavioral science as a strategic lens to decode the “why” behind the decisions made by healthcare professionals, patients, care partners, and other stakeholders. Biopharma decisions hinge on knowing why customers do what they do. Traditional research does a good job of capturing what stakeholders say but often misses the unconscious drivers, biases, emotions, and contexts that shape behavior. The result is an incomplete picture in the moments where clarity matters most, including when developing positioning strategies, planning product launches, and making major lifecycle decisions. "You don't need a survey to tell you that physicians see efficacy as the most important treatment decision driver," said Andrew Pilecki, Ph.D., Senior Market Research Director at Blue Matter. "What our clien
Blackfuel Emerges From Stealth with More Than $250 Million in Contracted Revenue to Build a Global AI Token Grid30.9.2026 15:00:00 CEST | Press release
First deployment scheduled to enter service in 2026, combining industrial-scale infrastructure, proprietary inference software and long-term customer commitments. Blackfuel today emerged from stealth with more than $250 million in contracted revenue under multi-year customer agreements, unveiling its ambition to build a global AI Token Grid. Pioneering the AI Token Grid, Blackfuel is building a network of architecture-specific accelerator clusters connected through a common software and commercial layer, designed to turn dedicated compute into measurable, reservable AI output. By collaborating with AMD and NTT DATA, Blackfuel is developing its European-operated inference capacity, beginning with a GPU cluster currently being delivered in Europe. "The cloud was built around virtual machines. The next infrastructure layer will be built around tokens. We are building Blackfuel to become one of the world's defining AI compute companies, starting with our first deployments in Europe. That m
934 Embeds Bluefin Payment Security into Juno to Advance Secure, Connected Hospitality Payments30.9.2026 15:00:00 CEST | Press release
Partnership brings PCI-validated P2PE and tokenization into 934’s connected hospitality payment infrastructure Bluefin, a global leader in payment and data security, and 934, a global provider of connected payment technology for the hospitality industry, today announced a partnership to integrate Bluefin’s payment security capabilities into Juno, 934’s hospitality payment platform. Hospitality businesses increasingly operate across connected payment environments spanning hotels, restaurants, resorts and other guest experiences. Behind those interactions are multiple systems, workflows and payment technologies that must work together while protecting sensitive payment data. Juno is designed to connect those experiences through a unified hospitality payment environment. By incorporating Bluefin’s security technology into the platform architecture, 934 can provide customers globally with access to PCI-validated point-to-point encryption (P2PE) for card-present payments and tokenization fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom